Zacks Investment Research upgraded shares of Catasys (NASDAQ:CATS) from a sell rating to a hold rating in a research note published on Thursday.
According to Zacks, “Catasys, Inc., formerly known as Hythiam, Inc., provides specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Company’s program seeks to improve member health by delivering medical and psychosocial interventions in combination with long term care coaching, including their proprietary treatment program for alcoholism and stimulant dependence. Catasys, Inc. is based in Los Angeles. “
Several other research firms have also weighed in on CATS. Taglich Brothers assumed coverage on shares of Catasys in a research note on Wednesday, October 18th. They set a speculative buy rating and a $8.00 price objective on the stock. Telsey Advisory Group assumed coverage on shares of Catasys in a research note on Wednesday, October 18th. They set a buy rating on the stock. Finally, ValuEngine lowered shares of Catasys from a hold rating to a sell rating in a research note on Saturday, October 21st.
Catasys (NASDAQ CATS) opened at $4.33 on Thursday. The firm has a market cap of $68.96, a PE ratio of -4.20 and a beta of 0.10. Catasys has a 52 week low of $3.30 and a 52 week high of $14.00.
Catasys (NASDAQ:CATS) last released its quarterly earnings data on Tuesday, November 14th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.04). equities research analysts forecast that Catasys will post -0.89 EPS for the current year.
WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/12/catasys-cats-upgraded-to-hold-at-zacks-investment-research.html.
Catasys, Inc provides data analytics based specialized behavioral health management and integrated treatment services to health plans and other third party payors. It offers OnTrak solution to improve treatment outcomes and lower the utilization of medical and behavioral health plan services. The companys OnTrak solution includes medical and psychosocial interventions; and a proprietary Web based clinical information platform and database, psychosocial programs, and integrated care coaching services.
Get a free copy of the Zacks research report on Catasys (CATS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catasys and related companies with MarketBeat.com's FREE daily email newsletter.